Adjuvant Chemotherapy for Completely Resected Non-Small Cell Lung Cancer
Journal of Lung Cancer 2003³â 2±Ç 1È£ p.6 ~ p.9
±è»óÀ§(Kim Sang-We) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ³»°úÇб³½Ç
Abstract
Lung cancer is the number one cause of cancer-related deaths in Korea. Non- small cell lung cancers account for about 80% of these cases. Because the long term survival of patients after a complete resection is poor, postoperative adjuvant chemotherapy seems to be a very promising concept. However, studies on postoperative chemotherapy, to date, have been disappointing. Recently, the International Adjuvant Lung Cancer Trial (IALT) reported an absolute 5% statistically significant 5-year survival benefit (p£¼0.03). Further studies, which could select patients favored with adjuvant chemotherapy, are necessary.
Å°¿öµå
Non-small cell lung cancer, Adjuvant chemotherapy
KMID :
0982820030020010006
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The International Adjuvant Lung Cancer Trial (IALT) reported an absolute 5% statistically significant 5-year survival benefit.